429 results about "Lung tissue" patented technology

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The invention belongs to the technical field of medical treatment, and discloses a pulmonary nodule segmentation method and system based on a diffusion model, and the method employs a potential space fusion method based on anatomical constraint, integrates the anatomical priori knowledge of lung tissue contour and the like through a variational auto-encoder (VAE), and combines a KL divergence constraint strategy. And the sensitivity of the model to a tiny focus is effectively improved. Secondly, a multi-modal collaborative optimization FSUNet architecture is constructed, and a cross-scale feature pyramid fusion mechanism is utilized to cooperate with a channel attention gating and dynamic noise scheduling algorithm, so that the expression ability of multi-dimensional features is enhanced. And finally, designing a Dice-Focal joint loss function to suppress complex background noise interference, and meanwhile, based on a forward diffusion-based noise sample generation strategy, remarkably reducing the dependence of the model on annotated data. Experimental results on an LIDC-IDRI data set show that the diffusion segmentation method based on multi-scale feature fusion not only shows excellent performance, but also shows excellent performance on an FPS index at the same time.

The invention relates to the technical field of image reconstruction, in particular to a lung puncture three-dimensional image reconstruction positioning system and method. The method comprises the following steps that CT scanning sequence data and chest wall multi-point infrared mark data of a patient are obtained, wherein the chest wall multi-point infrared mark data comprise respiration reference position data, real-time angular velocity data of a chest wall motion state and real-time acceleration data of each point of the chest wall; and inputting the real-time angular velocity data and the real-time acceleration data into a lung tissue nonlinear viscoelasticity prediction model based on a Maxwell model according to the chest wall multi-point infrared marking data to carry out iterative calculation so as to obtain lung tissue stress-strain relation data. According to the method, the non-feature region can be simplified while the grid density of the feature region is kept, the calculation burden is greatly reduced, and the detail and global consistency of reconstruction is ensured.

The invention discloses a novel marker for evaluating severity and prognosis of a dermatomyositis / anti-synthase syndrome related interstitial lung disease and application of the novel marker. According to the application disclosed by the invention, the content expression of sTREM-1 in serum of all patients with dermatomyositis / anti-synthase related interstitial lung diseases, especially patients with rapid progression type interstitial lung diseases, is found to be obviously increased through research. The content of the sTREM-1 in serum in patients with dermatomyositis / anti-synthase related interstitial lung diseases reflects the expression condition of the membrane receptor TREM-1 in lung tissues to a certain extent. According to the application disclosed by the invention, the risk of RP-ILD of patients suffering from dermatomyositis / anti-synthase complicated with interstitial lung diseases can be early warned at the early stage of the disease, and an effective technical means is provided for improving dermatomyositis / anti-synthase syndrome complicated with ILD, especially prognosis of the patients suffering from RP-ILD.

The invention provides a pulmonary nodule display method and device, electronic equipment and a storage medium, and the method comprises the steps: segmenting a three-dimensional reconstruction image of the chest of a target patient to obtain a preoperative segmentation image, the three-dimensional reconstruction image being obtained based on preoperative CT data, and the preoperative segmentation image comprising the position information of a pulmonary nodule; segmenting the video image of the intraoperative lung tissue of the target patient collected by the thoracoscope in real time to obtain an intraoperative segmented image; feature matching is conducted on the preoperative segmented image and the intra-operative segmented image, the lens pose of the thoracoscope is determined, the preoperative segmented image is mapped into a two-dimensional reference image based on the lens pose, and the two-dimensional reference image comprises the position information of the pulmonary nodule; and carrying out image registration on the two-dimensional reference image and the intra-operative segmented image, and carrying out pulmonary nodule marking on the intra-operative segmented image to obtain a video image for displaying pulmonary nodules in real time. The position of the pulmonary nodule in the operation is accurately displayed in real time in a non-invasive mode, and the operation efficiency is improved.

The invention discloses a compound derivative represented by a formula I or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt thereof. According to the application of a double protection strategy, diversified carrier fragments are introduced to 5-hydroxyl and hydroxylamine in N4-hydroxycytidine molecules, the N4-hydroxycytidine prodrug is invented, the affinity of lung cell membranes (phospholipid membranes) is improved, and the physicochemical properties of the drug are made to meet the requirements of the physiological environment of lung tissue. Therefore, the compound disclosed by the invention has a wide application prospect in the aspect of broad-spectrum respiratory virus resistance. # imgabs0 #

The invention provides a compound probiotic for relieving acute lung injury and application of the compound probiotic, and particularly discloses application of the compound probiotic consisting of bifidobacterium animalis YRK-12 and lactobacillus rhamnosus LRa-Y8 in preparation of a medicine for relieving the acute lung injury. Wherein the preservation number of the bifidobacterium animalis YRK-12 is CGMCC (China General Microbiological Culture Collection Center) No.28597; the preservation number of the lactobacillus rhamnosus LRa-Y8 is CGMCC (China General Microbiological Culture Collection Center) No. 34186. Experimental verification shows that the compound probiotics can remarkably relieve acute lung injury induced by lipopolysaccharide (LPS) through a synergistic effect; specifically, the weight loss rate of mice is reduced, pathological injuries of lung tissues are improved (the structural integrity of alveolar alveoli is maintained, and inflammatory cell infiltration is reduced), the levels of proinflammatory factors (IL-1beta, TNF-alpha and IL-6) in serum and lung tissues are reduced, and the level of anti-inflammatory factors (IL-4) is increased, so that the immune balance of the lung is regulated through an intestine-lung axis; and a safe and effective novel micro-ecological regulation strategy is provided for prevention and treatment of acute lung injury.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating sepsis-related acute lung injury and application thereof. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients in parts by mass: 5-15 parts of cassia twig, 5-15 parts of rheum officinale, 10-20 parts of peach kernel, 25-35 parts of gypsum and 10-20 parts of kudzu vine root. Animal experiments show that the traditional Chinese medicine composition can effectively improve lung tissue pathological manifestations of mice with sepsis-related acute lung injury by inhibiting polarization of M1 type macrophages, promoting polarization of M2 type macrophages, improving the infiltration level of neutrophils and inhibiting release of inflammatory factors. Therefore, the traditional Chinese medicine composition disclosed by the invention has a good treatment effect on acute lung injury related to sepsis.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The invention belongs to the technical field of biological medicine, and particularly relates to application of corynebacterium casei in preparation of medicine for preventing and treating lung injury. By constructing a radon inhalation-induced lung injury mouse model, after exposure at different radon levels, the weight of a mouse is reduced, the lung coefficient is increased, the tidal volume of the lung, the ventilation volume per minute and the maximum inspiration flow are reduced, the respiratory function is inhibited, the alveolar cavity of the mouse is abnormally expanded, the pulmonary septum is thickened and fractured, and more fibrin exudation is accompanied; the traditional Chinese medicine composition can be used for effectively inhibiting pulmonary fibrosis and lung injury due to obvious inflammatory infiltration beside bronchial tubes, extravasated blood in small blood vessels and lung tissue collagen deposition, and can be used for gavage of corynebacterium casei to effectively inhibit the above phenomena. Therefore, the corynebacterium casei can be used for preventing and treating lung injury, especially lung injury caused by radon exposure.

The invention discloses hydrogel bio-ink, a preparation method of the hydrogel bio-ink, a 3D printing biodegradable airway stent and application of the 3D printing biodegradable airway stent. The preparation method comprises the following steps that S1, lung tissue is subjected to freeze thawing, slicing, sequential decellularization of SDS and TritonX-100, air drying, smashing and cryopreservation, and a lung extracellular matrix is obtained; s2, performing sterilization and pepsin treatment on the lung extracellular matrix prepared in S1 to obtain a pretreated lung extracellular matrix; and S3, mixing methyl propionylated gelatin and an alginate solution, pouring the mixture into solid gel, gelatinizing the solid gel, and adding the pretreated lung extracellular matrix to prepare the hydrogel bio-ink. The prepared pig lung acellular extracellular matrix does not have an obvious nuclear structure, and DNA (Deoxyribonucleic Acid) determination shows that the concentration of an acellular group is obviously reduced (P is less than 0.01); along with the increase of the dECM concentration, the porosity is reduced, and the degradation time is prolonged; the airway stent is printed in a 3D biological printing mode, no obvious cytotoxicity (P is larger than 0.05) exists in a cytotoxicity experiment, and the mechanical property part of the airway stent is similar to that of a silicone stent.

The invention discloses a stem cell preparation for treating pulmonary fibrosis. The stem cell preparation is mesenchymal stem cell surface modified nanoparticles. The nanoparticles are ROS (reactive oxygen species) response type lipid polymer hybrid nanoparticles loaded with an anti-fibrosis drug. According to the invention, a hydrophobic drug and a hydrophilic anti-fibrosis drug can be simultaneously loaded through the reductive hybrid nanoparticles, and can be delivered to the lung by utilizing the inflammation targeting capability of stem cells. The polymer in the nanoparticles reacts with active oxygen in the microenvironment to promote drug release, and then the effect of protecting stem cells is achieved. The released medicine can induce dedifferentiation of myofibroblasts and inhibit apoptosis of vascular endothelial cells and endothelial mesenchymal transformation, and the mesenchymal stem cells release growth factors at the same time to promote angiogenesis, reconstruct capillary structures deleted in fibrosis areas, promote lung tissue regeneration and recover lung functions to achieve the effect of treating pulmonary fibrosis.

The utility model relates to a direction-variable puncture needle for lung tissue biopsy and a puncture sampling system, and belongs to the technical field of medical instruments. The puncture needle comprises a puncture trocar, a guide trocar and a sampling needle; a movable guide trocar is arranged in the hollow puncture trocar for percutaneous puncture in a penetrating manner; the guide trocar is provided with a bending part capable of controlling the turning direction; a movable bendable sampling needle is arranged in the hollow guide trocar in a penetrating manner; a sampling section is arranged at one end of the sampling needle away from an operator; the guide trocar is provided with a traction line for pulling the bending part of the guide trocar to change the sampling direction on a virtual plane formed by the puncture trocar and the sampling target; a mark used for marking the circumferential position of the traction line is axially arranged along the outer part of the guide trocar body; circumferential scales are arranged on the needle body circumference on the outer side of a human body along the puncture trocar. After the puncture needle is punctured into a human body, the sampling direction of the puncture needle can be changed according to the actual position of a sampling target, and the one-time puncture success rate is improved.

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.

The invention discloses an aza-four-membered ring connected pyrazolopyridine compound or pharmaceutically acceptable salt and application thereof, and the compound with the structure can be used as a novel high-selectivity PDE10A inhibitor for treating peripheral tissue diseases such as cardiac hypertrophy and cardiac dysfunction (heart failure), diabetes, hypertension, renal function impairment and renal fibrosis. Lung inflammation and pulmonary fibrosis, immune regulation disorder and cancers (colon cancer, ovarian cancer and lung cancer). Through strategies in two aspects, the inhibition effect of the compound on a PDE10A high-selectivity inhibitor is reduced while the inhibition effect of the compound on a central nervous system is reduced. Firstly, in the aspect of molecular structure modification, the structure of the pyrazolopyridine compound connected with the aza-four-membered ring is optimized, for example, the polar surface area of molecules is increased by increasing the proportion of the number of N, O and S atoms in the molecular structure, and the fat solubility is reduced; and hydrophilic groups are introduced to increase water solubility and the like, so that the permeability of the compound to the blood brain barrier BBB is reduced. And 2, targeted drug delivery of lung tissues is realized by means of a pharmaceutical preparation.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

The invention relates to the technical field of medical imaging, and discloses a peripheral lung cancer pleural invasion evaluation system based on ultrasonic targeted radiography, comprising: a double-frequency ultrasonic probe configured to independently work at different frequencies to realize depth imaging and high-resolution imaging of lung tissues and suitable for different types of lung lesions; the signal processing module can receive, analyze and process echo signals transmitted by the ultrasonic probe, generate images in real time and extract feature information; and the dynamic motion compensation module is used for automatically adjusting the emission time sequence and parameter setting of the ultrasonic signal based on the real-time breathing motion state of the patient. By adopting the design of the double-frequency ultrasonic probe and the core-shell structure, high-resolution imaging and depth detection of lung tissues are realized. By dynamically adjusting the thickness of the probe shell to be matched with the frequency, the system can adapt to complex tissue environments under different physiological conditions, and image definition and stability are ensured.

The utility model provides a simple pulmonary nodule positioning device for assisting endoscopic surgery, which comprises a positioning mechanism marked with scales, and a bipolar electrocoagulation device which can be matched with the positioning mechanism and is used for accurately positioning pulmonary nodules in the auxiliary endoscopic surgery is fixed on the positioning mechanism. And the bipolar electrocoagulation device is connected with a high-frequency generator with a control button. The simple pulmonary nodule positioning device used for assisting the endoscopic surgery is simple in structure and convenient to operate, can accurately position ground glass nodules in the lung by combining an expansion-collapse method, can improve the positioning accuracy of the pulmonary nodules in the surgery, achieves the purpose of accurately excising the pulmonary nodules, reduces excision of lung tissues while ensuring that the incisal margins are negative, and improves the operation efficiency. More lung functions are reserved, so that the operation effect is improved.

The invention belongs to the technical field of frozen slicing, and particularly relates to an animal lung tissue frozen embedding and slicing and space transcriptome sequencing method. In the first aspect, the animal lung tissue freezing and embedding method is provided and comprises the following steps that blood in animal lungs is replaced with first perfusate, and the first perfusate is selected from a first isotonic solution; liquid in the lung is replaced with second perfusate, the perfused lung is obtained, and the second perfusate comprises OCT and a second isotonic solution; and embedding the perfusion lung by adopting OCT (optical coherence tomography), and then quickly freezing. The lung is perfused with the perfusate formed by mixing OCT and the buffer solution, damage to the space structure and form can be reduced, and the tissue slice with the complete internal structure is obtained. Through experimental tests of different thicknesses of perfused lung tissue slices, the slices with the thickness of 10 microns are successfully obtained, in a space transcriptome experiment, the state that most cells belong to monolayer cells is achieved, and the data quality is improved.

Proposed is a composition for preventing or treating lung diseases. The composition may contain CD47-overexpressing mesenchymal stem cells as an active ingredient. CD47-overexpressing mesenchymal stem cells, even when not autologous, show a high survival rate in vivo and the ability to migrate to lung tissue, reduce the inflammatory response in lung tissue, and exhibit a fibrosis-inhibiting effect. CD47-overexpressing mesenchymal stem cells can be widely used for the prevention or treatment of various lung diseases related to inflammation or fibrosis of the lungs.

The invention relates to application of roxburgh rose-derived exosomes (RrNVs) in preparation of products for preventing, improving or treating acute lung injury (ALI). Specifically, the rosa roxburghii tratt exosome (RrNVs) can effectively inhibit inflammation, improve the acute lung injury symptom, reduce the release of inflammatory cells and inflammatory mediators in the acute lung injury state, and relieve the pulmonary edema condition, the lung tissue leakage condition and the lung capillary permeability condition in the inflammatory state. Meanwhile, the RrNVs can also regulate and control the intestinal flora structure, improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, and the discovery provides a basis for the RrNVs as potential functional food, medicine and the like of ALI.

The invention discloses a thoracic surgery pulmonary infection effusion drainage device and belongs to the technical field of medical instruments, the thoracic surgery pulmonary infection effusion drainage device comprises a drainage catheter structure, a filtering structure and a connecting assembly, the drainage catheter structure comprises an insertion tube, the two ends of the insertion tube are connected with a fixing tube and a hemispherical end respectively, and a partition plate is arranged in the insertion tube and the fixing tube; a plurality of drainage holes are formed in the end, close to the hemispherical end, of the insertion tube in the circumferential direction, and a medicine feeding hole is formed in the portion, above the drainage holes, of the insertion tube and communicated with the monitoring cavity. By means of the semispherical end and the drainage hole of the drainage catheter structure, lung tissue is prevented from being scratched when thoracic wall puncture is conducted, the lung tissue damage rate can be reduced to be smaller than or equal to 0.5%, drainage, pressure monitoring and drug administration are achieved through the double-cavity structure, one-time puncture is completed, and the pain of a patient is relieved; by arranging the partition plate, the drainage cavity and the monitoring cavity are isolated, liquid medicine is prevented from polluting an effusion sample, and the infection risk is reduced.

The invention provides application of Ulixertinib in treatment of lung tissue inflammation caused by novel coronavirus, and the Ulixertinib can effectively relieve the lung inflammatory infiltration degree after infection of the novel coronavirus, reduce the expression level of cytokines, chemotactic factors or NETs related proteins and inhibit formation of NETs. The invention provides a brand new treatment strategy for novel coronavirus infection, especially severe lung tissue inflammation caused by multiple infection of novel coronavirus.

The invention belongs to the technical field of lung tissue lesion positioning, and particularly relates to a lung tissue lesion position positioning system and method based on three-dimensional reconstruction. According to the method, overall and local two-stage registration is combined, whole-lung expansion errors are corrected, local deformation is compensated, the lesion position and image alignment is achieved, the three-dimensional lesion position is displayed through the augmented reality technology, doctors are helped to visually master spatial distribution of the focus in the body of a patient, the safety and the success rate of operation or needle biopsy are improved, and the operation efficiency is improved. Based on a breathing model and an elastic registration method, the method can adapt to lung compliance differences and breathing movement conditions of different patients, is particularly suitable for severe or old patients difficult to keep stable breathing, reduces the risk of blind penetration or excessive resection through accurate positioning, and reduces tissue damage and the occurrence rate of postoperative complications.

The invention relates to application of visceral odorobacter and outer membrane vesicles thereof in preparation of drugs for treating acute lung injury, and relates to the technical field of drugs. The modeling medicine lipopolysaccharide is applied to a mouse individual in a nasal dripping mode, the administration mode is that each mouse is administered once a day, and intragastric administration is carried out once a day after modeling is carried out for two days and lasts for 7 days. Experiments prove that visceral odorobacter and outer membrane vesicles of the visceral odorobacter reduce the number of M1 type alveolar macrophages by down-regulating proinflammatory factors IL-6, TNF-alpha and IL-1beta in lung tissues and inhibiting three proinflammatory factors IL-6, TNF-alpha and IL-1beta in serum, so that the effect of remarkably reversing acute lung injury is achieved. The visceral odor bacilli and the outer membrane vesicles thereof are used for preventing and treating the acute lung injury, and a new method and means are provided for clinically treating the acute lung injury.